AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
155 hedge funds and large institutions have $1.57B invested in Aimmune Therapeutics in 2019 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
6% more funds holding
Funds holding: 146 → 155 (+9)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Holders
155
Holding in Top 10
2
Calls
$16.3M
Puts
$8.33M
Top Buyers
| 1 | +$21.7M | |
| 2 | +$16.2M | |
| 3 | +$15.5M | |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$14.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.4M |
Top Sellers
| 1 | -$54.6M | |
| 2 | -$15.4M | |
| 3 | -$12.8M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.6M |
| 5 |
Bank of New York Mellon
New York
|
-$10.7M |